Hyperforin (Phloroglucinol)

Hyperforin is a phloroglucinol derivative found in St. John's wort that acts as a broad-spectrum neurotransmitter reuptake inhibitor. It modulates serotonin, norepinephrine, and dopamine levels through TRPC6 channel activation and synaptic membrane depolarization.

Origin & History

Hyperforin is a prenylated phloroglucinol derivative extracted from Hypericum perforatum (St. John's wort), a perennial herb native to Europe, western Asia, and North Africa. It is obtained through solvent extraction of the plant's aerial parts (flowers, leaves, stems) and standardized to specific hyperforin concentrations (0.5-5%) in commercial extracts.

Historical & Cultural Context

Hypericum perforatum containing hyperforin has been used in European folk medicine for approximately 2000 years as a wound healer, nerve tonic, and treatment for mood disorders, melancholy, and anxiety. Traditional Western herbalism employed it for depression-like symptoms and topical anti-inflammatory applications.

Health Benefits

• Reduces mild to moderate depression symptoms - RCTs show 5% hyperforin extracts reduced HAMD-17 scores by 10.3 points vs 7.9 for placebo (p=0.017)
• Exhibits dose-dependent antidepressant effects - Higher hyperforin content (5% vs 0.5%) showed superior efficacy in multiple trials
• Modulates neurotransmitter systems - Inhibits reuptake of serotonin, norepinephrine, and dopamine similar to conventional antidepressants
• May match SSRI effectiveness - Meta-review of 27 trials (n=3808) found favorable outcomes for mild-moderate depression
• Serves as biomarker for treatment adherence - Plasma hyperforin levels detected in compliant users, absent in 17% due to non-adherence

How It Works

Hyperforin activates TRPC6 cation channels in neuronal membranes, causing sodium influx and membrane depolarization. This leads to inhibition of serotonin, norepinephrine, dopamine, GABA, and glutamate reuptake transporters. The compound also modulates cortisol levels through 11β-hydroxysteroid dehydrogenase inhibition.

Scientific Research

Key clinical evidence includes two RCTs (PMID: 23196026, 9684948) with 147 outpatients each, demonstrating hyperforin dose-dependent antidepressant effects over 42 days. The NIH Hypericum Depression Trial (PMID: 15876903) with 340 patients found no overall efficacy versus placebo, though 17% non-adherence was noted, while a meta-review (PMID: 28064110) of 27 trials supported use in mild-moderate depression.

Clinical Summary

Multiple randomized controlled trials demonstrate hyperforin's antidepressant effects, with 5% hyperforin extracts reducing HAMD-17 depression scores by 10.3 points versus 7.9 for placebo (p=0.017). Dose-dependent effects are evident, with higher hyperforin concentrations (5% vs 0.5%) showing superior efficacy across trials. Most studies used standardized St. John's wort extracts containing 3-5% hyperforin in samples of 100-300 participants with mild to moderate depression. Evidence quality is moderate, with some studies showing publication bias.

Nutritional Profile

Hyperforin is a polyprenylated acylphloroglucinol derivative (molecular formula C35H52O4, MW 536.8 g/mol) and is not a nutritional source of macronutrients, vitamins, or minerals. It is the principal bioactive phloroglucinol compound found in Hypericum perforatum (St. John's Wort), typically concentrated in the reproductive structures (flowers and buds). Key biochemical and bioavailability details: • Concentration in dried St. John's Wort flowering tops: approximately 2–5% w/w in standardized pharmaceutical-grade extracts (e.g., WS 5570 extract standardized to 5% hyperforin); raw herb contains roughly 0.2–4.5% depending on harvest time and chemotype. • Co-occurring bioactive compounds in the native plant matrix include hypericin (0.1–0.3%), pseudohypericin, adhyperforin (structurally related acylphloroglucinol, present at ~0.2–1.9%), flavonoids (rutin, hyperoside, quercetin glycosides totaling 2–4%), and biflavones (amentoflavone, biapigenin). • Hyperforin is highly lipophilic (logP ~7–9) and chemically unstable; it is readily oxidized and degraded by light and oxygen, forming furohyperforin and other oxidation products, which significantly reduces effective concentration in poorly stabilized preparations. • Oral bioavailability is moderate but variable; peak plasma concentrations (Cmax) of approximately 150–300 ng/mL are reached 3–5 hours after a single 300 mg dose of extract containing ~5% hyperforin (≈15 mg hyperforin per dose). Steady-state plasma levels of ~100 ng/mL are achieved with standard t.i.d. dosing (900 mg extract/day providing ~45 mg hyperforin/day). • Elimination half-life is approximately 9–12 hours. Hyperforin is extensively metabolized hepatically, primarily via CYP3A4, and is itself a potent inducer of CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein through activation of the pregnane X receptor (PXR/SXR). • Primary mechanism of action involves activation of TRPC6 (transient receptor potential canonical 6) cation channels, leading to non-selective inhibition of neurotransmitter reuptake (serotonin, norepinephrine, dopamine, GABA, and L-glutamate) with IC50 values in the range of 0.05–0.6 µM. • No significant caloric, protein, fiber, or mineral contribution; hyperforin is consumed exclusively as a phytopharmaceutical bioactive, not as a food or nutritional supplement in the macronutrient sense. • Stability-enhanced formulations (e.g., hyperforin dicyclohexylammonium salt or CO2 supercritical extracts in lipid matrices) improve shelf-life and may enhance oral bioavailability by protecting against oxidative degradation.

Preparation & Dosage

Clinically studied doses: 900 mg/day of Hypericum perforatum extract (typically 3×300 mg), standardized to 0.5-5% hyperforin content. Major depression trials used 900-1500 mg/day. No data exists for isolated hyperforin powder; stabilized extracts prevent oxidation. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

SAMe, Rhodiola rosea, L-theanine, Omega-3 fatty acids, Vitamin D3

Safety & Interactions

Hyperforin induces CYP3A4 and P-glycoprotein, causing significant drug interactions with warfarin, oral contraceptives, cyclosporine, and HIV protease inhibitors. Common side effects include photosensitivity, gastrointestinal upset, dizziness, and fatigue in 10-15% of users. The compound may trigger serotonin syndrome when combined with SSRIs or MAOIs. Pregnant and breastfeeding women should avoid hyperforin due to insufficient safety data and potential hormonal effects.